Clinical Candida krusei isolates remain susceptible during extensive exposure to antifungal drugs

Medical Mycology

Volumn 48, Issue 1, 2010, Pages 79-84

  Hautala, Timo ^a,b   Kakko, Sakari ^a   Siitonen, Timo ^a   Sily, Marjaana ^a   Koistinen, Pirjo ^a   Koskela, Markku ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

Antifungal resistance; Candidemia; Immunosuppression

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ADULT; AGED; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA KRUSEI; CANDIDEMIA; CLINICAL ARTICLE; DRUG EXPOSURE; FEMALE; GENETIC ANALYSIS; HUMAN; LOADING DRUG DOSE; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; CANDIDA; CANDIDIASIS; CASE REPORT; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED;

ISSATCHENKIA ORIENTALIS;

ADULT; AGED; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED;

EID: 74949112429     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693780902725276     Document Type: Article

References (23)

1. Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non- Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect 2002; 50: 56-65.
2. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35: 627-630.
3. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008; 112: 2493-2499.
4. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and infl uences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-643.
5. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317.
6. Vos MC, Endtz HP, Horst-Kreft D, et al. Candida krusei transmission among hematology patients resolved by adapted antifungal prophylaxis and infection control measures. J Clin Microbiol 2006; 44: 1111-1114.
7. Hautala T, Ikaheimo I, Husu H, et al. A cluster of Candida krusei infections in a haematological unit. BMC Infect Dis 2007; 7: 97.
8. Bohme A, Ruhnke M, Buchheidt D, et al. Treatment of fungal infections in hematology and oncology - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82 ( Suppl. 2 ): S133-S140. (Pubitemid 37265300)
9. Spellberg BJ, Filler SG, Edwards JE Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42: 244-251.
10. Herbrecht R, Fluckiger U, Gachot B, et al. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. Eur J Cancer Suppl 2007; 5: 49-59.
11. Hakki M, Staab JF, Marr KA. Emergence of a C andida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 2006; 50: 2522-2524.
12. Kahn JN, Garcia-Effron G, Hsu MJ, et al. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 2007; 51: 1876-1878.
13. Pelletier R, Alarie I, Lagace R, Walsh TJ. Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med Mycol 2005; 43: 559-564.
14. Pfaller MA, Diekema DJ, Gibbs DL, et al. Candida krusei , a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008; 46: 515-521.
15. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008; 14: 398-405.
16. EUCAST Technical Note on voriconazole. Clin Microbiol Infect 2008; 14: 985-987.
17. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol. 2008; 46: 2620-2629.
18. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-1177.
19. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995; 20: 1531-1534.
20. Bellmann R. Clinical pharmacokinetics of systemically administered antimycotics. Curr Clin Pharmacol 2007; 2: 37-58.
21. Chryssanthou E, Cuenca-Estrella M. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol 2002; 40: 3841-3844.
22. Desnos-Ollivier M, Dromer F, Dannaoui E. Detection of caspofungin resistance in Candida spp. by Etest. J Clin Microbiol 2008; 46: 2389-2392.
23. Baixench MT, Aoun N, Desnos-Ollivier M, et al. Acquired resistance to echinocandins in Candida albicans : case report and review. J Antimicrob Chemother 2007; 59: 1076-1083.